# ulcerative colitis (UC) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 48064
- Completion tokens: 17594
- Reasoning tokens: 0
- Total tokens: 65658
- API requests reported: 3
- Elapsed seconds: 134.722
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: OpenAI

---
## Data-quality warning and scope

The input shows a strong disease-state signal: all 100 unique selected genes have FDR ≤0.05, with 40 upregulated and 60 downregulated genes. However, the table contains 175 retained rows representing 100 unique genes, including 43 duplicated genes/probes and composite probe/gene labels. The extremely small P values and uniformly significant results may reflect a large effect, technical or platform-related behavior, probe redundancy, or unmodeled tissue-composition differences. Therefore, the statistical directions are preserved as the direct evidence, but effect magnitudes should not be interpreted as causal or clinically validated.

The supplied GO/KEGG and STRING results were completed before synthesis and are treated as contextual annotations, not newly calculated enrichment or network statistics. No independent-cohort statistic was supplied; **external statistical validation was not performed**.

## 1. Overall biological interpretation

The UC mucosal profile is consistent with an inflamed, structurally remodeled colonic epithelium rather than a simple isolated immune signature. The dominant pattern combines:

- **Innate inflammatory and neutrophil-associated activation**, including strong increases in **S100A8** (log2FC 3.799), **CXCL1** (3.456), **CXCL2** (2.799), **CXCL3** (2.330), **LCN2** (2.668), **PI3** (2.208), and **PLA2G2A** (1.535).
- **Epithelial oxidative and antimicrobial stress**, particularly **DUOX2** (4.666), **DUOXA2** (2.892), **LCN2**, **PI3**, and **DEFB1** downregulation (−2.305).
- **Loss of epithelial transport, absorptive, metabolic, and barrier-associated functions**, with marked decreases in **AQP8** (−4.417), **SLC51A** (−3.711), **HMGCS2** (−3.445), **SLC38A4** (−3.067), **SLC16A1** (−2.375), **ABCG2** (−2.919), and **MEP1B** (−2.991).
- **Mucosal injury, extracellular-matrix remodeling, and repair**, reflected by **MMP3** (4.642), **CHI3L1** (4.590), **TNC** (2.579), **TIMP1** (1.969), **PRRX1** (2.907), and **PDPN** (2.539).
- **Mixed immune recruitment and regulatory signals**, including an immunoglobulin-containing transcript (1.891), **CTLA4** (2.616), **DAPP1** (2.204), **SOCS3** (2.786), **IL1RN** (2.876), and **IFI16** (1.386).

Taken together, the most defensible interpretation is **active mucosal inflammation accompanied by epithelial functional loss and a compensatory/remodeling response**. The data do not establish whether these changes initiate UC, result from inflammation, or reflect altered proportions of epithelial, stromal, myeloid, and lymphoid cells.

## 2. Core biological programs

### Program 1: Innate inflammatory chemokine and neutrophil-associated activation

- **Direction:** Upregulated in UC.
- **Supporting genes:** **S100A8**, **CXCL1**, **CXCL2**, **CXCL3**, **LCN2**, **PI3**, **PLA2G2A**, **CHI3L1**, and **VNN1**.
- **Relevant standardized pathways:** KEGG **IL-17 signaling pathway**; GO categories related to inflammatory response, chemokine activity, and leukocyte recruitment. The supplied pathway batch also identified IL-17 signaling.
- **Interpretation:** The coordinated increase in three CXC chemokines together with S100A8, LCN2, PI3, and PLA2G2A supports recruitment and activation of innate immune cells, particularly neutrophil-associated inflammation. This is more persuasive than relying on any one canonical inflammatory marker.
- **Evidence strength:** **Strong direct transcriptomic association**, because several functionally related genes show concordant increases with very small FDR values, for example S100A8 FDR 4.434e-11 and CXCL1 FDR 1.152e-15. The CXCL1/CXCL2/CXCL3 relationship is a **pathway/co-expression or network relationship**, not evidence of direct physical binding. STRING connectivity through **CXCR2** provides contextual receptor-network support.
- **Limitations:** The pattern may reflect increased neutrophil or inflammatory myeloid-cell abundance rather than activation of resident epithelial cells. IL-17 pathway annotation is contextual and was not independently enriched with a newly calculated P value.

### Program 2: Epithelial oxidative-stress and antimicrobial response

- **Direction:** Predominantly upregulated stress/defense response, with loss of at least one epithelial antimicrobial transcript.
- **Supporting genes:** **DUOX2**, **DUOXA2**, **LCN2**, **PI3**, **IFI16**, **TRIM29**, **DEFB1**, and **IL1RN**.
- **Relevant standardized pathways:** Reactome **Detoxification of Reactive Oxygen Species**; GO terms related to antimicrobial defense, oxidant generation, and innate immune response.
- **Interpretation:** **DUOX2** and its partner-like activating component **DUOXA2** are strongly increased, while LCN2 and PI3 support a mucosal antimicrobial response. In contrast, **DEFB1** is downregulated, indicating that the response is not a uniform enhancement of all epithelial defense mechanisms. **IL1RN** and **SOCS3** may represent counter-regulatory responses to inflammatory signaling.
- **Evidence strength:** **Strong direct dataset evidence** for DUOX2/DUOXA2 induction: DUOX2 log2FC 4.666, FDR 4.448e-26; DUOXA2 log2FC 2.892, FDR 1.117e-10. Their relationship is best described as **functional/regulatory pathway association**, not a demonstrated direct physical interaction in this dataset. Reactome and GO records provide pathway plausibility.
- **Limitations:** Transcript abundance does not demonstrate increased ROS production, epithelial barrier damage, or antimicrobial activity. Oxidative stress may be secondary to inflammation.

### Program 3: Loss of epithelial transport, absorptive metabolism, and luminal handling

- **Direction:** Downregulated in UC.
- **Supporting genes:** **AQP8**, **AQP7**, **SLC51A**, **SLC38A4**, **SLC16A1**, **SLC23A1**, **SLC23A3**, **ABCG2**, **HMGCS2**, **G6PC**, **MEP1B**, and **DEFB1**.
- **Relevant standardized pathways:** GO **Fluid Transport** and **Water Transport**; KEGG **Bile secretion**; Reactome **Passive transport by Aquaporins**. The supplied pathway batch identified these transport-related categories.
- **Interpretation:** The coordinated reduction of aquaporins, solute carriers, bile-acid transport machinery, and epithelial metabolic genes is consistent with impaired epithelial transport and absorptive specialization. The strongest examples are AQP8 log2FC −4.417, SLC51A −3.711, HMGCS2 −3.445, and SLC38A4 −3.067.
- **Evidence strength:** **Strong direct dataset evidence**, supported by multiple genes spanning water, nutrient, metabolite, and bile-acid handling. External annotations support the functions of AQP7 and AQP8, including Reactome passive aquaporin transport and the AQP8 association with bile secretion. This is **pathway co-membership**, not evidence that these proteins physically interact.
- **Limitations:** Decreased expression may reflect loss of mature absorptive epithelial cells, epithelial dedifferentiation, inflammation, medication effects, or altered nutritional state. The table alone cannot distinguish transcriptional repression from cell-composition change.

### Program 4: Extracellular-matrix remodeling, injury response, and mucosal repair

- **Direction:** Upregulated.
- **Supporting genes:** **MMP3**, **CHI3L1**, **TNC**, **TIMP1**, **PRRX1**, **PDPN**, **TGM2**, **SERPINB5**, **FILIP1L**, and **FREM2**.
- **Relevant standardized pathways:** GO extracellular region and extracellular matrix organization; Reactome extracellular-matrix organization where applicable.
- **Interpretation:** MMP3 and CHI3L1 indicate tissue injury and inflammatory remodeling, while TNC, PDPN, PRRX1, TGM2, and TIMP1 are compatible with stromal activation, matrix turnover, and repair. The simultaneous increase in MMP3 and TIMP1 suggests active matrix turnover with a compensatory inhibitor response rather than simply unrestricted proteolysis.
- **Evidence strength:** **Strong direct association** from multiple concordant genes, including MMP3 log2FC 4.642 and CHI3L1 4.590. The supplied STRING network links **FREM2, TGM2, and TNC** through **ITGB1**; this should be interpreted as network/pathway or extracellular-matrix association unless the underlying record specifically demonstrates a direct physical interaction for a particular pair.
- **Limitations:** Stromal-cell expansion, ulceration, fibrosis, and wound healing can all produce this pattern. The data do not establish persistent fibrosis or a causal role for any individual matrix gene.

### Program 5: Mixed adaptive-immune and counter-regulatory response

- **Direction:** Upregulated, but likely heterogeneous and composition-sensitive.
- **Supporting genes:** **CTLA4**, **DAPP1**, **SOCS3**, **IL1RN**, **IRAK3**, **IFI16**, **CD55**, and the immunoglobulin-containing transcript.
- **Relevant standardized pathways:** Immune-regulatory and cytokine-signaling GO/Reactome categories; the supplied annotations provide pathway and regulatory-network context but no independent pathway statistic.
- **Interpretation:** CTLA4 and an immunoglobulin-containing transcript suggest increased lymphoid or antibody-associated material, while DAPP1 supports immune-cell signaling. SOCS3, IRAK3, IL1RN, and CD55 are compatible with negative feedback or tissue-protective counter-regulation. This indicates a mixed inflammatory and regulatory state rather than uniformly escalating immune activation.
- **Evidence strength:** **Moderate direct evidence**, because the genes are significant and directionally compatible with immune involvement, but their cellular origin is unresolved. CTLA4 expression in bulk mucosa may primarily reflect infiltrating regulatory or activated T cells. Published and database records provide biological plausibility, but no independent UC cohort statistic was supplied.
- **Limitations:** This program is particularly vulnerable to cell-composition confounding and cannot be assigned to a specific immune subset without single-cell or spatial data.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological interpretability and validation value, not because external record counts establish statistical priority.

1. **DUOX2–DUOXA2 oxidative-defense module**
   - **Statistics:** DUOX2 log2FC 4.666, FDR 4.448e-26; DUOXA2 log2FC 2.892, FDR 1.117e-10.
   - **Role:** Epithelial oxidant generation and mucosal defense.
   - **Relationship:** Functional/regulatory association within the DUOX system; not automatically a direct physical interaction.
   - **Interpretation:** A strong supported hypothesis for epithelial oxidative stress, requiring measurement of ROS or enzyme activity.

2. **CXCL1–CXCL2–CXCL3 chemokine module**
   - **Statistics:** CXCL1 3.456, CXCL2 2.799, CXCL3 2.330; all FDR values are <2e-11.
   - **Role:** Innate leukocyte recruitment, especially neutrophil-associated signaling.
   - **Relationship:** Pathway co-membership and chemokine-receptor network association through CXCR2; not direct physical interaction among the chemokines.
   - **Interpretation:** One of the most coherent inflammatory modules in the dataset.

3. **S100A8–LCN2–PI3 inflammatory defense module**
   - **Statistics:** S100A8 3.799, LCN2 2.668, PI3 2.208; FDR values range from 4.434e-11 to 3.968e-19.
   - **Role:** Myeloid/neutrophil-associated inflammation and mucosal antimicrobial defense.
   - **Relationship:** Indirect inflammatory co-expression or pathway association; direct protein interaction is not established here.
   - **Interpretation:** Strong disease-state marker module, but highly sensitive to infiltrating-cell abundance.

4. **AQP8/AQP7 transport module**
   - **Statistics:** AQP8 −4.417, AQP7 −2.322; FDR 1.603e-13 and 4.037e-20, respectively.
   - **Role:** Water, glycerol, and epithelial transport.
   - **Relationship:** Shared aquaporin functional pathway; STRING records involving AQP7/AQP8 and AQP11/AQP12A should not be interpreted as direct binding without pair-specific physical-interaction evidence.
   - **Interpretation:** Strong evidence for a transport-associated disease-state change.

5. **SLC51A–ABCG2–HMGCS2 epithelial metabolic/transport axis**
   - **Statistics:** SLC51A −3.711, ABCG2 −2.919, HMGCS2 −3.445.
   - **Role:** Bile-acid/xenobiotic transport and epithelial metabolic specialization.
   - **Relationship:** Pathway co-membership and indirect functional relationship.
   - **Interpretation:** Potentially important for altered luminal metabolite handling, but not sufficient to infer altered bile-acid flux.

6. **MMP3–TNC–TIMP1 remodeling module**
   - **Statistics:** MMP3 4.642, TNC 2.579, TIMP1 1.969.
   - **Role:** Matrix turnover, tissue injury, and repair.
   - **Relationship:** Functional/pathway association; TNC and TIMP1 do not constitute a direct interaction based on the supplied evidence.
   - **Interpretation:** Strong remodeling signature with possible compensatory inhibition.

7. **CHI3L1–PRRX1–PDPN stromal/injury-response module**
   - **Statistics:** CHI3L1 4.590, PRRX1 2.907, PDPN 2.539.
   - **Role:** Stromal activation, wound response, and extracellular remodeling.
   - **Relationship:** Indirect or cell-state association; likely influenced by stromal-cell abundance.
   - **Interpretation:** Important candidate for spatial validation rather than immediate causal assignment.

8. **CTLA4–DAPP1 immune-regulatory module**
   - **Statistics:** CTLA4 2.616, DAPP1 2.204.
   - **Role:** Activated/regulatory lymphocyte signaling.
   - **Relationship:** Immune-pathway co-membership; not a direct physical interaction.
   - **Interpretation:** Supports immune infiltration or activation, but bulk data cannot identify the responsible cell type.

9. **IL1RN–SOCS3–IRAK3 counter-regulatory module**
   - **Statistics:** IL1RN 2.876, SOCS3 2.786, IRAK3 1.782.
   - **Role:** Negative feedback in inflammatory signaling.
   - **Relationship:** Regulatory/pathway association; the genes may respond to common inflammatory stimuli, but causality is not demonstrated.
   - **Interpretation:** Suggests attempted limitation of inflammation rather than proving effective immunoregulation.

10. **BRINP3**
   - **Statistics:** downregulated, log2FC −2.133, FDR 6.953e-12.
   - **Role:** Candidate epithelial or mucosal disease-associated gene.
   - **Relationship:** The supplied literature includes a UC mucosal transcriptomics study specifically implicating underexpression of BRINP3 (PMID: **25171508**).
   - **Interpretation:** This is literature-concordant contextual support, not independent statistical replication of the present cohort.

## 4. Validation priorities

### 1. Validate epithelial oxidative stress and DUOX2 activity  
**Class:** Mechanistic hypothesis

- **Why prioritize it:** DUOX2 and DUOXA2 are among the strongest upregulated genes, and their coordinated direction is biologically coherent.
- **Current dataset evidence:** DUOX2 log2FC 4.666, FDR 4.448e-26; DUOXA2 log2FC 2.892, FDR 1.117e-10.
- **External support:** Reactome annotates oxidative-stress and ROS-related processes for relevant genes; this is pathway evidence, not causal or independent-cohort evidence.
- **Next step:** Measure DUOX2/DUOXA2 protein, epithelial localization, ROS production, oxidative-damage markers, and epithelial barrier function in UC and control biopsies or organoids.
- **Conclusion level:** **Supported hypothesis**, not established mechanism.

### 2. Validate the CXCL1/CXCL2/CXCL3–CXCR2 inflammatory axis  
**Class:** Interaction / network hypothesis

- **Why prioritize it:** Three related chemokines are independently upregulated, providing stronger module-level evidence than a single-gene association.
- **Current dataset evidence:** CXCL1, CXCL2, and CXCL3 are all increased with FDR values <2e-11.
- **External support:** The supplied STRING/network evidence connects these chemokines through CXCR2. This is receptor-network evidence and does not prove ligand-receptor activity in the sampled tissue.
- **Next step:** Use spatial transcriptomics or immunostaining to identify producing cells, quantify CXCR2-positive infiltrates, and test chemotaxis or pathway blockade in ex vivo tissue or organoid–immune-cell systems.
- **Conclusion level:** **Supported hypothesis**.

### 3. Determine whether transporter loss reflects epithelial repression or cell-composition change  
**Class:** Confounding or composition check

- **Why prioritize it:** AQP8, SLC51A, HMGCS2, SLC38A4, ABCG2, and related genes show a coherent decrease, but this could result from loss of mature absorptive epithelium.
- **Current dataset evidence:** Examples include AQP8 log2FC −4.417, SLC51A −3.711, HMGCS2 −3.445, and SLC38A4 −3.067.
- **External support:** GO and Reactome annotate water transport, passive aquaporin transport, bile secretion, and epithelial metabolic functions. These annotations support plausibility but do not distinguish cell loss from transcriptional regulation.
- **Next step:** Perform single-cell or spatial transcriptomics, quantify epithelial subtype markers and histologic cell proportions, and validate transporter protein abundance and functional flux.
- **Conclusion level:** **Supported hypothesis**, with substantial composition uncertainty.

### 4. Test whether MMP3/CHI3L1/TNC reflect reversible repair or persistent remodeling  
**Class:** Mechanistic hypothesis

- **Why prioritize it:** Matrix-remodeling genes are strongly increased and may distinguish active injury from chronic structural change.
- **Current dataset evidence:** MMP3 log2FC 4.642, CHI3L1 4.590, TNC 2.579, and TIMP1 1.969.
- **External support:** Extracellular-region and matrix annotations, together with the FREM2/TGM2/TNC–ITGB1 network record, support a remodeling interpretation. These are contextual pathway/network records, not proof of fibrosis.
- **Next step:** Localize these genes to epithelial, fibroblast, or myeloid compartments; measure matrix deposition, protease activity, and longitudinal behavior during flare and remission.
- **Conclusion level:** **Supported hypothesis**.

### 5. Evaluate a compact tissue biomarker panel  
**Class:** Biomarker

- **Why prioritize it:** A panel spanning inflammation and epithelial dysfunction may be more robust than a single marker: **S100A8, LCN2, CXCL1 or CXCL2, DUOX2, AQP8, and MMP3**.
- **Current dataset evidence:** Each is significantly altered, with directions and values preserved above.
- **External support:** The literature retrieval includes UC biomarker and co-expression studies, including PMID **41029776**; however, the supplied record does not provide an independent statistic directly validating this proposed panel. Literature support may overlap with database annotations.
- **Next step:** Predefine the panel, test it by qPCR/protein assays in an independent UC-control cohort, and evaluate specificity against infection, Crohn’s disease, medication exposure, and disease severity.
- **Conclusion level:** **Exploratory hypothesis** until independently tested.

## 5. Evidence grounding and conflicts

- **Direct dataset evidence:** All 100 unique genes are statistically significant in the supplied analysis, but duplicate/probe structure and possible technical saturation require caution.
- **Pathway and ontology evidence:** The supplied batch supports fluid/water transport, carboxylic-acid transport, IL-17 signaling, bile secretion, and related extracellular or membrane categories. These are annotations or recurrence summaries, not independent P values.
- **Network evidence:** STRING and OmniPath records support selected relationships, including CXCL1/CXCL2/CXCL3 through CXCR2 and FREM2/TGM2/TNC through ITGB1. Relationship type is source-dependent; co-membership or predicted association must not be upgraded to direct physical interaction.
- **Disease and literature evidence:** BRINP3 has a UC-specific literature record for mucosal underexpression (PMID **25171508**). The retrieved UC biomarker literature includes PMID **41029776** and treatment-response analysis PMID **38059894**. These records support plausibility but do not replicate the current effect sizes.
- **Independent validation:** No external cohort-level log2FC, P value, FDR, sample size, or model was supplied. Thus, pathway recurrence, database coverage, and literature support are not replication.
- **Potential conflicts:** The simultaneous increase in antimicrobial/stress genes and decrease in DEFB1 shows that epithelial defense is heterogeneous rather than uniformly activated. Similarly, increased CTLA4 and IL1RN/SOCS3/IRAK3 alongside inflammatory chemokines suggests concurrent immune activation and negative feedback, not a simple “pro-inflammatory” versus “anti-inflammatory” state.

## 6. Major limitations and alternative explanations

1. **Cellular composition:** Increased S100A8, CTLA4, immunoglobulin transcripts, and CXCL genes may reflect infiltrating myeloid or lymphoid cells, while decreased AQP8, HMGCS2, and transporter genes may reflect loss of mature absorptive epithelium. Single-cell or spatial profiling, histologic deconvolution, and cell-type-specific immunostaining are priorities.

2. **Disease severity and treatment exposure:** Active ulceration, corticosteroids, biologics, antibiotics, diet, and disease duration could alter inflammatory, metabolic, and epithelial-repair programs. Clinical covariate adjustment and stratification by activity and treatment are needed.

3. **Bulk-tissue and causality limitations:** The results identify associations in colonic mucosa, not initiating mechanisms. Longitudinal sampling, organoids, epithelial–immune co-culture, and perturbation experiments are required to test causality.

4. **Technical redundancy and probe annotation:** Forty-three genes have duplicated rows or composite/probe labels, and several entries are not straightforwardly interpretable as single canonical genes. Probe-level quality control, remapping, collapsing rules, and sensitivity analysis are necessary.

5. **Lack of external statistical validation:** The very small P values and broad significance across all selected genes should be confirmed in an independent cohort using the same tissue definition, normalization, covariates, and disease-control contrast. Until then, the most reliable conclusions are the internally coherent inflammatory, epithelial-transport, and remodeling patterns, not clinical effectiveness or therapeutic causation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=18, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
